• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer.].

作者信息

Yang Lu, Lu Qi-Ying, Wu Mei-Na, An Tong-Tong, Zhao Jun, Guo Qing-Zhi, Duan Jian-Chun, Wang Jie

机构信息

Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2009 Nov;32(11):830-4.

PMID:20079293
Abstract

OBJECTIVE

To investigate whether the clinical characteristics, treatment modalities and prognosis of elderly (>/= 70 years) patients with advanced non-small cell lung cancer (NSCLC) differed from those of young (</= 45 years) patients.

METHODS

This retrospective study included 256 elderly patients and 143 young patients with chemotherapy-naive advanced NSCLC treated at Department of Thoracic Medical Oncology in Beijing Cancer Hospital from March 1995 to May 2007. All patients received first-line chemotherapy. Clinical data were analyzed using chi-square test, Log-lank test, Cox regression and Kaplan-Meier survival analysis.

RESULTS

(1) Women, adenocarcinoma and stage IV disease were more common in young patients (46.2% vs 22.3%, P = 0.000, 71.3% vs 54.7%, P = 0.001 and 72.7% vs 61.7%, P = 0.026), when compared with elderly patients. The smoker rate in young women was also higher (95.5%). (2) The disease control rate (DCR) of first-line chemotherapy was similar between young and elderly patients (P = 0.257). Platinum-based combination chemotherapy was a benefit factor for the disease control rate of first-line chemotherapy, whatever in young patients (P = 0.047) or in elderly patients (P = 0.028). Hematologic toxicities were similar between these 2 groups. (3) There was no significant difference in terms of median progression free survival (PFS) or median overall survival (OS) between young and elderly patients (P = 0.399 and P = 0.869, respectively). (4) Easten Cooperative Oncology Group (ECOG) score, DCR for first-line chemotherapy and the regimen of second-line chemotherapy were all independent prognostic factors (P = 0.000, 0.021 and 0.000 in young patients, P = 0.007, 0.000 and 0.000 in elderly patients, respectively).

CONCLUSION

Women, adenocarcinoma and stage IV disease were more common in young patients when compared with elderly patients. The increased incidence of NSCLC in young women may be associated with the high smoker rate. The OS and PFS were not significantly different between young and elderly patients.

摘要

相似文献

1
[A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer.].
Zhonghua Jie He He Hu Xi Za Zhi. 2009 Nov;32(11):830-4.
2
Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.培美曲塞单药治疗对比培美曲塞联合铂类药物作为二线治疗方案用于晚期非小细胞肺癌。
Chin Med J (Engl). 2009 Oct 20;122(20):2472-6.
3
[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].多西他赛单药与多西他赛联合铂类药物在晚期非小细胞肺癌二线治疗中的比较
Zhonghua Yi Xue Za Zhi. 2009 Jun 9;89(22):1544-8.
4
[Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].不同治疗方案作为小细胞肺癌二线治疗的疗效与安全性比较
Zhongguo Fei Ai Za Zhi. 2015 May;18(5):280-8. doi: 10.3779/j.issn.1009-3419.2015.05.05.
5
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.克唑替尼治疗间变性淋巴瘤激酶阳性的晚期非小细胞肺癌与化疗作为一线治疗的比较。
BMC Cancer. 2018 Jan 3;18(1):10. doi: 10.1186/s12885-017-3720-8.
6
[Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].培美曲塞联合铂类用于初治晚期非小细胞肺癌的化疗效果
Zhonghua Jie He He Hu Xi Za Zhi. 2012 Feb;35(2):97-101.
7
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: a retrospective analysis of single institution.一线铂类化疗治疗老年晚期非小细胞肺癌的预后因素:单中心回顾性分析
J BUON. 2012 Jul-Sep;17(3):533-6.
8
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.贝伐单抗联合卡铂和紫杉醇治疗老年晚期非小细胞肺癌患者的疗效:东部肿瘤协作组4599试验分析
J Clin Oncol. 2008 Jan 1;26(1):60-5. doi: 10.1200/JCO.2007.13.1144.
9
A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.老年晚期鳞状非小细胞肺癌患者每周使用纳米白蛋白结合型紫杉醇作为二线化疗的安全性和疗效的回顾性分析。
Clin Interv Aging. 2016 Feb 19;11:167-73. doi: 10.2147/CIA.S97363. eCollection 2016.
10
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.厄洛替尼对比化疗二线治疗晚期预后不良非小细胞肺癌患者的疗效和安全性(TITAN):一项随机、多中心、开放性、III 期研究。
Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.